{"retracted":false,"update":{"timestamp":1421798400000,"doi":"10.1007/s10549-015-3263-0","type":"correction"},"doi":"10.1007/s10549-013-2810-9","journal":"Breast Cancer Research and Treatment","publisher":"Springer Nature","title":"Erratum to: A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure"}
